Orlistat
Also known as: Xenical · Alli (previously Orlistat GSK) · ALLI
General information only. Anpheros does not diagnose and does not recommend treatment. Talk to a doctor or pharmacist about your situation. In an emergency, call 112 (or your local emergency number).
In short
In the European Union, the Alli brand of orlistat is indicated for weight loss in overweight adults with a body mass index (BMI) of 28 kg/m2 or more, and it should be taken in conjunction with a mildly hypocaloric, lower-fat diet. Also in the European Union, the Xenical brand is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a BMI of 30 kg/m2 or more, or overweight patients with a BMI greater than 28 kg/m2 who have associated risk factors. Treatment with Xenical should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight measured at the start of therapy. In the United States, the ALLI brand is used for weight loss in overweight adults aged 18 years and older when used along with a reduced-calorie and low-fat diet.
From: Source: European Medicines Agency (EMA), Alli (previously Orlistat GSK) — EPAR, 05/12/2024. © European Medicines Agency. · Source: European Medicines Agency (EMA), Xenical — EPAR, 10/05/2023. © European Medicines Agency. · Data provided by the U.S. Food and Drug Administration.
AI-generated summary of the sources cited on this page, checked automatically against them. Not reviewed by a clinician; not medical advice.
Codes
- RxNorm
- 37925 orlistat
- EMA
- EMEA/H/C/000154, EMEA/H/C/000854
Official indications
Quoted unchanged from official product information, in English. Listed alphabetically by product, not ranked.
FDA (USA) ALLI
Use for weight loss in overweight adults, 18 years and older, when used along with a reduced-calorie and low-fat diet
Data provided by the U.S. Food and Drug Administration.
Document date: 20260318 · Official document →
EMA (EU) Alli (previously Orlistat GSK)
Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet.
Source: European Medicines Agency (EMA), Alli (previously Orlistat GSK) — EPAR, 05/12/2024. © European Medicines Agency.
Document date: 05/12/2024 · Official document →
EMA (EU) Xenical
Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors. Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.
Source: European Medicines Agency (EMA), Xenical — EPAR, 10/05/2023. © European Medicines Agency.
Document date: 10/05/2023 · Official document →
Other treatments A–Z
What people report
Not enough data yet. Anonymous counts appear here only for groups of at least 20 people who agreed to share them.
External resources
Questions
What is Orlistat approved for in the European Union?
Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet. (Source: European Medicines Agency (EMA), Alli (previously Orlistat GSK) — EPAR, 05/12/2024. © European Medicines Agency.)
Sources and attribution
- Source: European Medicines Agency (EMA) — EPAR. © European Medicines Agency.
- Data provided by the U.S. Food and Drug Administration.
- Names other than the official source titles: Anpheros translations and plain-language names, made with AI assistance and checked automatically; the source names are in English.
- This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
- Source: European Medicines Agency (EMA), Alli (previously Orlistat GSK) — EPAR, 05/12/2024. © European Medicines Agency.
- Source: European Medicines Agency (EMA), Xenical — EPAR, 10/05/2023. © European Medicines Agency.
Anpheros Search catalog 2026.10.5, published 17 October 2026. About the data →
About this page. This page brings together public information from official sources, each cited where it is used. It is not medical advice, it is not a diagnosis, and it does not tell you which treatment to take.
Treatments. Indications are quoted unchanged from official product information (European Medicines Agency, U.S. Food and Drug Administration). They describe what a medicine is approved for, not whether it is right for you. Approved uses can differ between countries. Always read the package leaflet and follow your doctor's or pharmacist's advice.
What people report. Figures marked "reported by Anpheros users" are anonymous counts from at least 20 people who agreed to share them. They show what people report, not what works, and they are not clinical evidence.
Links between terms. "May be associated with" means the link appears in a cited source. It does not mean you have that condition.
In an emergency, call 112 (or your local emergency number). Do not delay seeking medical help because of something you read here.